FDA Clears Once-Weekly Insulin Efsitora to Ease Type 2 Diabetes Management

Type 2 diabetes is one of the most consequential age-related metabolic conditions, driving cardiovascular disease, kidney decline, neuropathy, and accelerated biological aging. Improving glycemic control — and adherence to insulin therapy — directly affects long-term healthspan outcomes for millions of adults.

The FDA has approved efsitora alfa (brand name Onswik), a once-weekly basal insulin developed by Eli Lilly, as an adjunct to diet and exercise for adults with type 2 diabetes. The therapy delivers stable basal insulin levels over a full seven-day period, reducing injection burden by more than 300 shots per year compared to once-daily regimens. Improved adherence resulting from simpler dosing schedules could meaningfully improve long-term glycemic outcomes and reduce complications.

Approval rested on results from four QWINT phase III trials enrolling over 3,400 participants globally. Across all four studies — covering insulin-naive patients, those switching from daily basal insulin, and those on complex basal-bolus regimens — efsitora demonstrated non-inferior HbA1c reductions compared to insulin glargine U-100 and insulin degludec U-100. One trial also confirmed efficacy in patients concurrently using GLP-1 receptor agonists, a common real-world combination.

The safety profile was broadly comparable to existing daily basal insulins. Key adverse effects include hypoglycemia, injection site reactions, weight gain, and edema. Prescribers are cautioned about co-administration with thiazolidinediones due to fluid retention risk, and the drug carries warnings around hypokalemia and medication errors inherent to concentrated formulations.

Efsitora is not indicated for type 1 diabetes or pediatric patients. As the second once-weekly basal insulin approved in the US — following icodec (Awiqli) cleared in March — it expands meaningful options for adults whose long-term metabolic health depends on sustainable insulin therapy. Reduced injection frequency may prove especially important for older adults managing complex polypharmacy regimens.